India, Sept. 22 -- On Tuesday, MediWound Ltd. (MDWD), a company based in enzymatic therapeutics for tissue repair, announced that it has been awarded additional $3.3 million by the U.S Department of War, in non-dilutive funding to speed up the development of a room-temperature-stable formulation of NexoBrid as a non-surgical debridement solution for battlefield burn care.
On the Nasdaq, the shares were trading 3.72 percent up at $13.81.
The additional funding brings the total program budget to $21.8 million. The program will support development of a room-temperature-stable formulation and the submission of an IND application to the U.S. FDA.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
MediWound i...